Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633723 | 1.00 | SOS1 (0.35) | SOS1SOS2CRBNGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL2635420 | 0.98 | SOS1 (0.34) | SOS1SOS2CRBNGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL2635419 | 0.97 | SOS1 (0.33) | SOS1SOS2CRBNGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL2635368 | 0.91 | GRIN1 (0.35) | SOS1SOS2CRBNGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL2635366 | 0.90 | GRIN1 (0.34) | SOS1SOS2CRBNGRIN1GRIN2A | |
| SCHEMBL24717655 | 0.89 | CRBN (0.43) | SOS1SOS2CRBNGRIN1GRIN2A | |
| SCHEMBL20474682 | 0.83 | CHRM2 (0.34) | CRBNGRIN1GRIN2APIK3CAMTOR | |
| Hydrochloric Acid SCHEMBL32683860 | 0.81 | CHRM2 (0.33) | CRBNGRIN1GRIN2APIK3CAMTOR | |
| SCHEMBL17082037 | 0.79 | CRBN (0.33) | CRBNCYP3A4CYP2D6USP2ALDH1A1 | |
| SCHEMBL13460109 | 0.78 | GRIN1 (0.40) | CRBNGRIN1GRIN2APIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514797-A1 | SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2025-03-05 | — | — | EP | disclosed |
| CN-119053598-A | Substituted 7- (pyrimidin-4-yl) quinolin-4 (1H) -one compounds as cyclin dependent kinase inhibitors | 百济神州有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023208172-A1 | SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BEIGENE , LTD. (KY) | 2023-11-02 | — | — | WO | disclosed |
| EP-2852591-A1 | L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5]DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS | Novartis AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013164790-A1 | L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5 ] DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| WO-2012164473-A1 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-8124601-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| EP-2215095-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2215095-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2009067392-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090130056-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | SOS1 539/4885SOS2 1905/4885CRBN 2898/4885 |
| US-20090130056-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | SOS1 3900/4885SOS2 4134/4885CRBN 4268/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | SOS1 539/4885SOS2 1905/4885CRBN 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.